• CME Information
• Table of Contents
• Challenging Existing Paradigms
• Targeted Antibody Therapy
  • Anti-VEGF Antibody (Bevacizumab) in Combination with Chemotherapy
  • Anti-EGFR Antibody (Cetuximab) in Combination with Chemotherapy
  • Using Markers to Select Patients for Anti-EGFR Antibody Therapy
  • Using EGFR Mutations to Select Patients for First-line EGFR TKI Therapy (Erlotinib, Gefitinib)
  • A Monoclonal Antibody Against the IGF-IR
• Role of Maintenance Therapy
  • Optimal Duration of Chemotherapy
  • Pemetrexed, Docetaxel, and Erlotinib in Maintenance Therapy
• New Ventures in Up-front Supportive Care
  • Integration of Early Palliative Care
  • Brain Metastases
• References
• Register & Receive
  CME Credit
• Download Activity PDF
• InforMEDical Home

InforMEDical
Communications, Inc.
83 Acton Street
Carlisle, MA 01741
tel: 978-318-9582
fax: 978-318-9583
info@informedicalcme.com

A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.

Advancing Treatment of Bladder Cancer

A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.

InforMEDical Communications, Inc. • 83 Acton Street • Carlisle, MA 01741
tel: 978-318-9582 • fax: 978-318-9583 • email: info@informedicalcme.com

Challenging Existing Paradigms for Optimal First-line Treatment of Advanced NSCLC

Thomas J Lynch, Jr, MD

Targeted Antibody Therapy with Chemotherapy in First-Line NSCLC

Targeted Antibody Therapy with Chemotherapy in First-Line NSCLC Anti-VEGF Antibody (Bevacizumab) in Combination with Chemotherapy in First-line Treatment of NSCLC: Common Questions Answered

Jared Weiss, MD, and Tracey Evans, MD

Anti-EGFR Antibody (Cetuximab) in Combination with Chemotherapy in First-line Treatment of NSCLC

Natasha Leighl, MD, MMSc, FRCPC

Using Markers to Select Patients for Anti-EGFR Antibody Therapy

Glenwood D Goss, MD, FCPSA, FRCPC

Using EGFR Mutations to Select Patients for First-line EGFR TKI Therapy (Erlotinib, Gefitinib)

Lecia V Sequist, MD, MPH

A Monoclonal Antibody Against the IGF-IR for the Treatment of NSCLC

Daniel D Karp, MD, and Antonio Gualberto, MD, PhD

Role of Maintenance Therapy

Defining the Optimal Duration of Chemotherapy in Advanced NSCLC

Panos Fidias, MD

Pemetrexed, Docetaxel, and Erlotinib in Maintenance Therapy

Nasser H Hanna, MD

New Ventures in Up-front Supportive Care

Integration of Early Palliative Care in the Treatment of Metastatic NSCLC

Jennifer Temel, MD

Brain Metastases

April F Eichler, MD, MPH, Jay S Loeffler, MD, and Tracy T Batchelor, MD

References